Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nls Pharmaceutics Ltd WT (NLSPW)

Nls Pharmaceutics Ltd WT (NLSPW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,980 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/01/70
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0110 +62.73%
on 10/24/25
0.0324 -44.75%
on 10/16/25
+0.0001 (+0.56%)
since 09/30/25
3-Month
0.0110 +62.73%
on 10/24/25
0.0324 -44.75%
on 10/16/25
+0.0009 (+5.29%)
since 07/30/25
52-Week
0.0009 +1,888.89%
on 04/07/25
0.0698 -74.36%
on 12/04/24
+0.0032 (+21.77%)
since 10/30/24

Most Recent Stories

More News
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL"

NLSPW : 0.0179 (-3.24%)
NLS : 0.8204 (+11.20%)
NCEL : 2.91 (-12.61%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

ZURICH , Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

ZURICH , Oct. 29, 2025 /PRNewswire/ --  NLS Pharmaceutics Ltd.  (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

ZURICH and NESS ZIONA, Israel , Oct. 29, 2025 /PRNewswire/ --  NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and  Kadimastem Ltd. (TASE: KDST) ("Kadimastem")...

NLSPW : 0.0179 (-3.24%)
KMSTF : 5.0600 (-0.78%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

ZURICH , Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.  (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

The equity financing is at a 10% premium to the market share price1

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating the potential...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

ZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)

Business Summary

NLS Pharmaceutics Ltd. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of therapies for rare and complex central nervous system disorders. The company's principal product candidate includes Quilience(R). NLS Pharmaceutics Ltd. is based in Switzerland.

See More

Key Turning Points

3rd Resistance Point 0.0269
2nd Resistance Point 0.0239
1st Resistance Point 0.0209
Last Price 0.0179
1st Support Level 0.0149
2nd Support Level 0.0119
3rd Support Level 0.0089

See More

52-Week High 0.0698
Fibonacci 61.8% 0.0435
Fibonacci 50% 0.0353
Fibonacci 38.2% 0.0272
Last Price 0.0179
52-Week Low 0.0009

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar